DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe
The E3 SUMO ligase PIAS2 is expressed at high levels in differentiated papillary thyroid carcinomas but at low levels in anaplastic thyroid carcinomas (ATC), an undifferentiated cancer with high mortality. We show here that depletion of the PIAS2 beta isoform with a transcribed double-stranded RNA-directed RNA interference (PIAS2b-dsRNAi) specifically inhibits growth of ATC cell lines and patient primary cultures in vitro and of orthotopic patient-derived xenografts (oPDX) in vivo. Critically, PIAS2b-dsRNAi does not affect growth of normal or non-anaplastic thyroid tumor cultures (differentiated carcinoma, benign lesions) or cell lines. PIAS2b-dsRNAi also has an anti-cancer effect on other anaplastic human cancers (pancreas, lung, and gastric). Mechanistically, PIAS2b is required for proper mitotic spindle and centrosome assembly, and it is a dosage-sensitive protein in ATC. PIAS2b depletion promotes mitotic catastrophe at prophase. High-throughput proteomics reveals the proteasome (PSMC5) and spindle cytoskeleton (TUBB3) to be direct targets of PIAS2b SUMOylation at mitotic initiation. These results identify PIAS2b-dsRNAi as a promising therapy for ATC and other aggressive anaplastic carcinomas., This work was supported by Agencia Estatal de Investigación (AEI, Spain), co-funded by the European Union, projects’ codes BFU2013-46109-R, BFU2016-76973-R, PID2019-110437RB-I00, PDC2021-121621-I00 and PID2022-140149OB-I00 to C.V.A. This work has received financial support from the Xunta de Galicia (Centro singular de investigación de Galicia accreditation 2019-2022) and the European Union (European Regional Development Fund - ERDF). J.M.C.-T. is supported by grant no. ISCIII-PI23/00722, and PI19/01316 from Instituto de Salud Carlos III, State Research Agency (Spain), co-funded by the European Union. L.F. is funded by Italian Ministry of Health - Ricerca Corrente. T.S. is recipient of a research contract from the Miguel Servet Program from the Instituto de Salud Carlos III, Ref. CPII17/00027, co-funded by the European Union., Peer reviewed
Proyecto:
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 BFU2013-46109-R
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 BFU2016-76973-R
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2019-110437RB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PDC2021-121621-I00
,
AEI PID2022-140149OB-I00
,
ISCIII PI19-01316
DOI: http://hdl.handle.net/10261/365517, https://api.elsevier.com/content/abstract/scopus_id/85192881022
HANDLE: http://hdl.handle.net/10261/365517, https://api.elsevier.com/content/abstract/scopus_id/85192881022